Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial of its antidiabetic combination therapy, IcoSema (insulin icodec + semaglutide), in patients with type 2 diabetes (T2D) inadequately controlled on daily basal insulin. In comparison to insulin glargine plus insulin aspart, once-weekly IcoSema demonstrated non-inferiority, achieving a 0.6% reduction in HbA1c at week 52, thereby meeting its primary endpoint.
Additionally, patients receiving IcoSema experienced an average weight loss of 3.6 kg, while the control group saw a 3.2 kg weight gain. The therapy also reported lower rates of severe or clinically significant hypoglycemia.
According to the press release, IcoSema is currently undergoing two additional Phase III trials to further evaluate its efficacy and safety compared to insulin icodec alone and semaglutide alone.- Flcube.com
